ERBB2 and breast cancer: Furthermore, in breast cancer, the interaction between HLA-G and the NK cell receptor KIR2DL4 amplifies the susceptibility of HER2-positive breast cancer cells to trastuzumab, elucidating the mechanisms underlying the resistance to trastuzumab (5).